Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX): Grabar Law Office is Investigating Claims on Your Behalf as Securities Fraud Class Action Survives Motion to Dismiss

Philadelphia, Pennsylvania--(Newsfile Corp. - October 7, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) prior to May 11, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.

Please visit https://grabarlaw.com/the-latest/amylyx-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

WHY? Key allegations of a recently filed securities fraud class action complaint filed against Amylyx Pharmaceuticals, Inc., (NASDAQ: AMLX) and certain of its officers, have now survived a motion to dismiss.

The underlying complaint alleges that, Amylyx Pharmaceuticals, Inc., through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects in that: (i) Defendants had overstated Relyvrio's commercial prospects; (ii) patients were discontinuing treatment with Relyvrio after six months; (iii) the rate at which new patients were starting treatment with Relyvrio was decreasing; (iv) accordingly, Defendants had also overstated Relyvrio's prescription rate; (v) Defendants attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing Relyvrio's prescription data; and (vi) as a result, Defendants' public statements were materially false and misleading at all relevant times. Then on April 4, 2024, Amylyx announced it was pulling Relyvrio from the market.

Specifically, on November 9, 2023, defendants issued a press release reporting that a slowdown in new subscribers and an increase in discontinuations had resulted in a failure to meet anticipated Q3 2023 earnings. Defendants admitted that only 60% of patients remained in treatment after six months and corporate share value fell more than 30% in response to that news. In March, 2024, defendants reported that the drug had failed to produce meaningful results in its Phase III trials. Share price fell another 80% and shortly thereafter defendants announced that they would withdraw Relyvrio from the market.

On September 30, 2025, the court determined that certain key allegations survived the defendants' motion to dismiss the underlying class action complaint.

WHAT YOU CAN DO NOW: If you purchased Amylyx Pharmaceuticals, Inc., (NASDAQ: AMLX) prior to May 11, 2023, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/amylyx-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $AMLX #Amylyx

Attorney Advertising Disclaimer

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269518